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a b s t r a c t
Vpx encoded by HIV-2 and SIVsm enhances retroviral reverse transcription in macrophages in vitro by
mediating the degradation of the host SAMHD1 protein that hydrolyzes dNTPs and by elevating cellular
dNTP levels. Here we employed RT-SHIV constructs (SIV encoding HIV-1 RT) to investigate the
contribution of Vpx to the potency of NRTIs, which compete against dNTPs, in monocyte-derived
macrophages (MDMs) and activated CD4þ T cells. Relative to HIV-1, both SIV and RT-SHIV exhibited
reduced sensitivities to AZT, 3TC and TDF in MDMs but not in activated CD4þ T cells. However, when SIV
and RT-SHIV constructs not coding for Vpx were utilized, we observed greater sensitivities to all NRTIs
tested using activated CD4þ T cells relative to the Vpx-coding counterparts. This latter phenomenon was
observed for AZT only when using MDMs. Our data suggest that Vpx in RT-SHIVs may underestimate the
antiviral efﬁcacy of NRTIs in a cell type dependent manner.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human immunodeﬁciency virus type 1 (HIV-1) infection con-
tinues as a pandemic. The majority of those infected with HIV-1
will progress to AIDS unless strictly adhering to combined anti-
retroviral therapy (cART). All current optimal combined anti-HIV-1
treatment regimens include at least 2 nucleos(t)ide reverse tran-
scriptase inhibitors (NRTIs) in combination with a third drug from
one of the three following classes: (i) non-nucleoside reverse
transcriptase inhibitors (NNRTIs), (ii) protease inhibitors (PIs)
boosted with ritonavir, or (iii) an integrase/strand transfer inhi-
bitor (INSTI) (Humphreys et al., 2010; Lee et al., 2014). Even with
cART, however, the development of antiretroviral (ARV) resistance
remains a formidable obstacle that often requires patients to
switch to different drugs and may be considered the primary
cause of reduced drug efﬁcacy (Moniz et al., 2014; Stanojevic et al.,
2014). Recent work, however, indicates that the host restriction
factor, sterile alpha motif and histidine/aspartic acid containing
domain protein 1 (SAMHD1), also affects NRTI efﬁcacy against
HIV-1 (Amie et al., 2013; Ballana et al., 2014; Huber et al., 2014).
Understanding all facets of how currently available ARVs are
affected at the molecular/cell level facilitates the conception of
more efﬁcacious drugs and facilitates progress toward a functional
cure (Benard et al., 2011; Ekouevi et al., 2014; Ren et al., 2002;
Witvrouw et al., 2004).
NRTIs exert their anti-HIV-1 effect by out-competing cellular
dNTPs for incorporation into the growing proviral DNA during reverse
transcription (Balzarini, 2000; Gao et al., 1993). The concentration of
cellular dNTPs available for proviral DNA synthesis is affected by
SAMHD1 phosphohydrolase activity and thought to impact non-
dividing target cell types such as macrophages in particular. SAMHD1
phosphohydrolase activity leads to dNTPs degradation to deoxynu-
cleosides (dNs) and triphosphates (Goldstone et al., 2011; Powell et al.,
2011). SAMHD1 suppresses viral replication by depleting cellular dNTP
concentrations, which, in turn, ultimately restricts the availability of
dNTPs for proviral DNA synthesis in macrophages. Recently, studies
have shown SAMHD1 does not degrade NRTIs containing chemically
altered sugar moieties (Amie et al., 2013; Ballana et al., 2014; Huber et
al., 2014). Thus, it is conceivable that SAMHD1, which delays HIV-1
reverses transcription by depleting dNTP substrates, further sup-
presses HIV-1 replication by enhancing NRTI potency against HIV-1.
This favorable outcome, however, may not necessarily translate to the
treatment of HIV-2 infections.
Human immunodeﬁciency virus type 2 (HIV-2) infection is an
additional and important cause of HIV disease in West Africa and
has limited spread to other regions of the world (da Silva et al.,
2008; de Silva et al., 2013; Mansson et al., 2010). The 2013 World
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Health Organization guidelines recommend the combined use of
either three NRTIs or two NRTIs plus one protease inhibitor (PI) as
the initial cART regimen for HIV-2 infection (Benard et al., 2011;
Gupta et al., 2014). However, the clinical, immunological, and
virological outcomes for recommended HIV-2 cART are suboptimal
(Benard et al., 2011; Ekouevi et al., 2014). Although there likely
exist many factors that contribute to the suboptimal clinical
outcome observed for the recommended treatment, there exists
some in vitro evidence that may, at least, partially account for this
observation. For example, it is well known that HIV-1 and HIV-2
NRTI-resistance mutation development differs in vivo (Smith et al.,
2009). It has been suggested that structural differences in reverse
transcriptase (RT) may account for the discrepancy between NRTI
potency in HIV-1 and HIV-2 infections (Boyer et al., 2006) and
recent work has highlighted the potential role of viral protein X
(Vpx) in reducing NRTI efﬁcacy in vitro (Amie et al., 2013; Ballana
et al., 2014; Huber et al., 2014).
Vpx is encoded by HIV-2 and some lineages of simian immuno-
deﬁciency virus (SIV) but not HIV-1 (Fregoso et al., 2013). Vpx
augments viral infectivity in non-dividing cells (Kappes et al., 1991)
by the degradation of SAMDH1 (Hrecka et al., 2011; Laguette et al.,
2011) and consequently increasing dNTP concentrations in primary
human cells (Baldauf et al., 2012; Berger et al., 2011; Hrecka et al.,
2011; Kim et al., 2012; Laguette et al., 2011; Lahouassa et al., 2012; St
Gelais et al., 2012; White et al., 2012; Wu, 2012). In addition to
hydrolyzing deoxynucleoside triphosphates, SAMHD1 has been
reported to have ribonuclease activity (Choi et al., 2015; Ryoo et al.,
2014), making its role in lentiviral infections more complex and not
completely understood (Seamon et al., 2015; White et al., 2013).
SAMHD1 is found in both cycling (activated CD4þ T cells) and non-
dividing cells (macrophage, dendritic and resting CD4þ T cells) target
cell types. However, SAMHD1 restriction of HIV has only been
reported in non-dividing cells (Baldauf et al., 2012; Berger et al.,
2011; Descours et al., 2012; Hrecka et al., 2011; Julg et al., 2010;
Laguette et al., 2011; Riveira-Munoz et al., 2014). This lack of antiviral
activity in cycling cells has been attributed to both reduction in
SAMHD1 protein level and T592 phosphorylation of SAMHD1, which
may regulate ribonuclease activity (Welbourn et al., 2013; White et al.,
2013) and may inﬂuence dNTPase activity (Pauls et al., 2014a, 2014b;
Ruiz et al., 2015; Yan et al., 2015). Therefore, SAMHD1 should have a
minimal impact on HIV/SIV infection in activated CD4þ T cells. Vpx
may have additional roles important for HIV-2/SIV biology, including
modulation of the interferon response (Dragin et al., 2013; Goujon et
al., 2013), assisting the preintegration complex transport into the
nucleus (Cheng et al., 2008; Fujita et al., 2012; Pancio et al., 2000) or
promoting cell cycle arrest (Bouzar et al., 2003).
Since NRTIs must outcompete dNTPs during reverse transcrip-
tion (Gao et al., 1993), it is likely that an increase in dNTP
concentrations may reduce NRTI efﬁcacy in the context of HIV-2/
SIV infections (Amie et al., 2013). Indeed, previous work from our
group showed that pretreating activated CD4þ T cells and
monocyte-derived macrophages (MDMs) with virus-like particles
(VLPs) containing Vpx led to an increase in cellular dNTP concen-
trations that directly compete with NRTIs, consequently reducing
their potency (Amie et al., 2013). More recently, Huber et al.
showed similar results in which AZT, TDF, d4T and EFdA became
less effective at inhibiting infection in cell lines not expressing
SAMHD1, whereas ddI and 3TC sensitivity did not change (Huber
et al., 2014). However, Ballana et al. (2014) reported that the
presence of Vpx only reduced AZT and d4T potency out of a variety
of NRTIs tested, suggesting that only thymidine analog NRTIs are
affected in this context. These reported studies employed VSV-G-
pseudotyped VLPs to introduce Vpx to target SAMHD1 in the cell
types tested, which is a unnatural way to delivery Vpx, and did not
directly evaluate the contribution of different RTs in these different
viruses. Thus, here, we compared HIV-1, SIV (as a surrogate for
HIV-2) and RT-SHIV to evaluate NRTI efﬁcacy in the context of
virion-associated Vpx and RT origin. We found that sensitivity to
NRTIs was comparable for HIV-1, SIV and RT-SHIV in activated
CD4þ T cells. Interestingly, SIVΔVpx and RT-SHIVΔVpx were more
sensitive to AZT, 3TC and TDF as compared to parental control
viruses in CD4þ T cells. When NRTI sensitivity was evaluated in
MDMs, HIV-1, SIVΔVpx and RT-SHIVΔVpx infection were most
sensitive to AZT, independent from the RT examined. The data
reported here provide an additional explanation, that both cell
type and virion-associated Vpx inﬂuences sensitivity to NRTIs.
Results
HIV-1, SIV and RT-SHIV show similar sensitivity to NRTI in activated
CD4þ T cells using a single-cycle GFP expression infection assay
Previous studies tested the effect of the SAMHD1/Vpx interplay
on HIV-1 infection (Baldauf et al., 2012; Bobadilla et al., 2012;
Hrecka et al., 2011; Kim et al., 2012; Laguette et al., 2011;
Lahouassa et al., 2012; Pauls et al., 2012; St Gelais et al., 2012;
White et al., 2012, 2013). Fewer studies have examined the
inﬂuence of SAMHD1 on NRTI efﬁcacy, which employed Vpx-
containing virus-like-particles (VLPs) to deliver the packaged Vpx
protein to the target cells (Amie et al., 2013; Ballana et al., 2014;
Huber et al., 2014). However, in natural infections, Vpx-encoding
lentiviruses such as HIV-2 and SIVsm not only deliver their
packaged Vpx protein to the target cells but also express Vpx
from the integrated proviral DNAs in the infected cell. In addition,
there exists evidence that the structural differences between the
RTs encoded by HIV-1, HIV-2 and SIV to account for the observed
differences in AZT resistance development (Herschhorn and Hizi,
2010; Ren et al., 2002). These structural differences appear to
translate to the biochemical properties of RT such as enzyme/
substrate ﬁdelity and NRTI incorporation rates (Bakhanashvili and
Hizi, 1992; Diamond et al., 2001; Lloyd et al., 2014; Skasko et al.,
2009; Taube et al., 1997). Thus, it is conceivable that the differ-
ences between HIV-1 and SIV RTs may impact NRTI efﬁcacy in
addition to the SAMHD1-mediated dNTP metabolism alteration.
Activated CD4þ T cells are very permissive to HIV-1 infection as
a result of high expression of the CD4 receptor on the cell surface,
high cellular dNTP concentrations and modulation of SAMHD1
(Welbourn et al., 2013; White et al., 2013). First we evaluated the
contribution of RT differences in the presence of Vpx to NRTI
efﬁcacy in activated CD4þ T cells. For this, we replaced SIV RT with
HIV-1 RT to create a RT-SHIV vector. As shown in Fig. 1, we tested
RT-SHIV (ﬁlled circle) in tandem with HIV-1 (ﬁlled triangle) and
SIV (ﬁlled square) against a variety of NRTIs in our CD4þ T cell
infection assay. We observed zidovudine (AZT; Fig. 1A), lamivudine
(3TC; Fig. 1B), tenofovir disoproxil fumarate (TDF; Fig. 1C), and
dideoxycytidine (ddC; Fig. 1D) showed little differences in sensi-
tivity among these three viruses. As shown in Table 1, the ratio of
IC50 for SIV and RT-SHIV to that of HIV-1, and IC50 of RT-SHIV to
that of SIV, were less than two-fold for all drugs tested. As controls,
we utilized the integrase inhibitor raltegravir (RAL; Fig. 1E), and
the NNRTI etravirine (ETR; Fig. 1F). RAL inhibited infection of all
three viral constructs within two-fold of each other (Table 1),
whereas ETR only inhibited HIV-1 and RT-SHIV infections in CD4þ
T cells, validating the RT differences between these three viruses.
Vpx contributes to NTRI sensitivity in activated CD4þ T cells.
To evaluate the contribution of Vpx to NRTI efﬁcacy, SIVΔVpx and
RT-SHIVΔVpx vectors were generated and tested in tandemwith SIV
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Fig. 1. Dose–response of NRTIs in CD4þ Tcells challengedwith VSV-G-pseudotyped HIV-1, SIV and RT-SHIV. Percent inhibition (y-axis) of CD4þ Tcells treatedwith increasing concentrations
(x-axis) of AZT (A), 3TC (B), TDF (C) ddC (D), RAL (E), and ETR (F), and then challengedwith VSV-G-pseudotypedHIV-1 (ﬁlled diamonds), SIV (ﬁlled squares) and RT-SHIV (ﬁlled circles). Dashed
line transects curve to show where 50% inhibition occurs. Data points depict the means and standard error of the means from three to four independent experiments.
Table 1
IC50 vales for CD4þ T cells.
IC507SD [nM]
Treatment n HIV-1 SIV RT-SHIV Fold change
Mean SD Mean SD Mean SD SIV/HIV-1 RT-SHIV/HIV-1 RT-SHIV/SIV
AZT 3 14.8 4.3 9 1.5 8.7 2.6 0.6 0.6 1
3TC 3 193 44 289 30 154 40 1.5 0.8 0.5
TDF 4 6 2.5 8.6 5.7 6.4 2.7 1.4 1.1 0.7
ddC 3 66.8 35.3 96.8 35.3 57.2 8.7 1.5 0.9 0.6
ETR 3 4.9 1.7 – – 4.4 1.4 – 0.9 –
RAL 3 5 1.4 9.7 3 6.3 1 1.9 1.3 0.6
SIV SIVΔVpx RT-SHIV RT-SHIVΔVpx
Mean SD Mean SD Mean SD Mean SD SIV/SIVΔVpx RT-SHIV/RT-SHIVΔVpx
AZT 3 120 102 9 4.2 84.4 66.2 8 3.9 13.3 10.6
3TC 3 347 83.2 114 29 206 61.6 67 21.7 3 3.1
TDF 3 12.7 9.8 2.1 1.4 10.9 8.4 1.9 1.2 6 5.7
RAL 3 9.7 3 13.9 9.2 6.3 1.1 6 1.1 0.7 1.1
ETR 4 – – – – 2.9 1.6 2.3 1.1 – 1.3
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and RT-SHIV against a limited number of NRTIs. We found that
SIVΔVpx (open square) versus SIV (ﬁlled square) and RT-SHIVΔVpx
(open circle) versus RT-SHIV (ﬁlled circle) exhibited signiﬁcantly (n)
lower IC50s to AZT, 3TC and TDF (Fig. 2A, B and C, respectively). For
the controls, all viruses were similarly sensitive to RAL (Fig. 2D),
whereas only RT-SHIV and RT-SHIVΔVpx viruses were sensitive to
ETR (Fig. 2E; 1.3-fold) as expected. Fold change comparisons for the
viruses are displayed in Table 1.
Since activated CD4þ T cells already have high cellular dNTP
levels well above the Km for reverse transcriptase (Kennedy et al.,
2010; Lenzi et al., 2014), we did not expect Vpx to affect viral
sensitivity to any NRTIs. Our observation implies that the virion-
associated Vpx may have additional roles in regulating viral
sensitivity to NRTIs in activated CD4þ T cells, in addition to
regulating SAMHD1 antiviral activities in macrophages (Kim
et al., 2012; St Gelais and Wu, 2011).
HIV-1, SIV and RT-SHIV demonstrate different sensitivities towards
NRTIs in MDMs
Previous studies reported VLPs reduce anti-HIV-1 activity of
various NRTIs primarily in macrophages, supporting that SAMHD1
affects NRTI sensitivity of HIV-1 by modulating cellular dNTP
levels (Amie et al., 2013; Ballana et al., 2014; Huber et al., 2014).
Using a single-cycle GFP expression infection assay for MDMs, we
observed signiﬁcantly greater HIV-1 sensitivity to AZT (Fig. 3A)
relative to SIV and RT-SHIV (Table 2). For 3TC IC50 values (Fig. 3B),
HIV-1 was 2.6-fold more sensitive than SIV, whereas RT-SHIV was
comparable to HIV having a 1.3-fold IC50 value difference. All three
viruses showed comparable trends in sensitivity for TDF (Fig. 3C)
and ddC (Fig. 3D), with IC50 values within two-fold of each other
(Table 2). Moreover, RAL (Fig. 3E) inhibited infection of all three
viral constructs comparably, whereas ETR (Fig. 3F) only inhibited
Fig. 2. Dose–response of NRTIs in activated CD4þ T cells challenged with molecular clones that code, or do not code, for Vpx. Percent inhibition (y-axis) of CD4þ T cells
treated with increasing concentrations (x-axis) of AZT (A), 3TC (B), TDF (C), RAL (D) and ETR (E) before challenge with SIV (ﬁlled squares), SIVΔVpx (open squares), RT-SHIV
(ﬁlled circles) and RT-SHIVΔVpx (open circles). Dashed line transects curve to show where 50% inhibition occurs. Signiﬁcant differences in dose–response curves are
indicated with an asterisk (*). Data points depict the means and standard error of the means from three to four independent experiments.
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Fig. 3. Dose–response of ARVs in MDMs challenged with VSV-G-pseudotyped HIV-1, SIV and RT-SHIV expressing GFP in vitro. Percent inhibition (y-axis) of MDMs treated
with increasing concentrations (x-axis) of AZT (A), 3TC (B), TDF (C) ddC (D), RAL (E), and ETR (F), and then challenged with VSV-G-pseudotyped HIV-1 (ﬁlled diamonds), SIV
(ﬁlled squares) and RT-SHIV (ﬁlled circles). Dashed line transects curve to show where 50% inhibition occurs. Signiﬁcant differences in dose–response curves are indicated
with an asterisk (*). Data points depict the means and standard error of the means from four to ﬁve independent experiments.
Table 2
IC50 vales for MDMs.
IC507SD [nM]
Treatment n HIV-1 SIV RT-SHIV Fold change
Mean SD Mean SD Mean SD SIV/HIV-1 RT-SHIV/HIV-1 RT-SHIV/SIV
AZT 3 10.1 4.6 164 144 217 186 16.2 21.4 1.3
3TC 3 131 71 338 20 166 66 2.6 1.3 0.5
TDF 4 8.1 5.5 7.3 5.4 4.3 2.4 0.9 0.5 0.6
ddC 3 33.7 45.1 62 22 54.7 45.2 1.8 1.6 0.9
ETR 3 4.8 4.3 – – 6.1 4.2 – 1.3 –
RAL 3 19.6 1.3 12.2 3.5 12.4 5.4 0.6 0.6 1
SIV SIVΔVpx RT-SHIV RT-SHIVΔVpx
Mean SD Mean SD Mean SD Mean SD SIV/SIVΔVpx RT-SHIV/RT-SHIVΔVpx
AZT 5 105 196 16.4 2.6 143 201 11.3 6 6.4 12.7
3TC 5 123 237 103 94 119 35.4 68.5 71.1 1.2 1.7
TDF 5 4.2 3.2 11.4 11.6 10.4 6.6 9.7 6.4 0.4 1.1
RAL 4 26 20 16.1 14.5 10.1 9.1 4.1 2.9 1.6 2.5
ETR 4 – – – – 12 4 5 1.4 – 2.4
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HIV-1 and RT-SHIV infection, conﬁrming the RT differences in
these three viral constructs.
Recently, Huber et al. and Ballana et al. showed VpxþVLP
treatment decreased sensitivity towards AZT using both cell lines
and human primary MDMs and CD4þ T cells, while observing very
little change in sensitivities towards other NRTIs (Ballana et al.,
2014; Huber et al., 2014). Our observation that the IC50 values of
SIV and RT-SHIV to most NRTIs tested are relatively similar to
these reports (Table 2), suggesting that the RT difference in SIV
and RT-SHIV does not signiﬁcantly contribute to their sensitivity to
NRTIs tested in MDMs.
Depletion of Vpx results in an increase sensitivity towards AZT in
MDMs.
Since previous studies used VLPs containing Vpx to counteract
SAMHD1, we directly tested the role of virion-associated Vpx in
viral sensitivity to NRTIs in MDMs. The SIVΔVpx (open squares)
and RT-SHIVΔVpx (open circles) vectors (Fig. 4A) were more
sensitive to AZT as compared to their parental vectors, SIV (ﬁlled
squares) and RT-SHIV (ﬁlled circles). As displayed in Table 2, the
IC50 values for SIV/SIVΔVpx and RT-SHIV/RT-SHIVΔVpx were 6.4-
and 12.7-fold, respectively. The sensitivity of these viruses to 3TC
(Fig. 4B) and TDF (Fig. 4C) were comparable and IC50 values were
within 2-fold range (Table 2). The RAL (Fig. 4D) and ETR (Fig. 4E)
controls were more effective in RT-SHIVΔVpx than RT-SHIV vector,
give fold changes of 2.5- and 2.4-fold, respectively. Overall, these
data indicate that the ΔVpx viruses were more sensitive to AZT
treatment in MDMs, whereas Vpx does not signiﬁcantly inﬂuence
viral sensitivity towards other NRTIs.
Discussion
HIV-1 does not code for Vpx. However, non-human primate
models used to evaluate anti-HIV-1 RT inhibitor efﬁcacy often
Fig. 4. Dose–response of NRTIs in MDMs challenged with molecular clones that code, or do not code, for Vpx. Percent inhibition (y-axis) of MDMs treated with increasing
concentrations (x-axis) of AZT (A), 3TC (B), TDF (C), RAL (D) and ETR (E) before challenge with SIV (ﬁlled squares), SIVΔVpx (open squares), RT-SHIV (ﬁlled circles) and RT-
SHIVΔVpx (open circles). Dashed line transects curve to show where 50% inhibition occurs. Signiﬁcant differences in dose–response curves are indicated with an asterisk (*).
Data points depict the means and standard error of the means from four to ﬁve independent experiments.
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employ SIV encoding HIV-1 RT in lieu of SIV RT; HIV-1 RT is
substituted in place of SIV RT given the differences between these
enzymes and NNRTI efﬁcacy (Ambrose et al., 2004, 2014; Balzarini
et al., 1995; North et al., 2014; Wang et al., 2014; Witvrouw et al.,
2004). Although the importance of substituting HIV-1 RT in lieu of
SIV RT in this context is recognized, the relationship between Vpx
and evaluation of NRTI efﬁcacy in the context of RT-SHIV con-
structs, to our knowledge, has not been addressed prior to this
report.
Vpx-mediated degradation of SAMHD1 increases dNTP concen-
trations in MDMs (Lahouassa et al., 2012). This would conceivably
increase dNTP/NRTI-TP competition as substrates for RT (Amie et al.,
2013; Ballana et al., 2014; Huber et al., 2014). Recent work has
suggested that RT efﬁciencies are different among SIV and HIV-1
according to dNTP concentrations (Lenzi et al., 2014; Skasko et al.,
2009) and postulates that HIV-1 RT evolved to be more efﬁcient at
low dNTP concentrations. Thus, the observation that NRTIs have
similar lower activities against SIV and RT-SHIV in macrophages
relative to HIV-1 andΔVpx counterpart constructs is expected since
the presence of Vpx increases dNTP concentrations in the cytoplasm
where reverse transcription takes place; higher dNTP concentra-
tions is likely directly proportional to NRTI/dNTP competition.
In this study we evaluated the contributions of virion-associated
Vpx, and also RT-SHIV to allow us to test the role of RTs in NRTI
sensitivity with respect to Vpx. For MDMs, our studies showed that
SIV and RT-SHIV were less sensitive towards AZT, ddC and 3TC as
compared to HIV-1. The sensitivity of HIV-1 to AZT, 3TC and ddC in
MDMs were consistent with recent reports (Ballana et al., 2014;
Huber et al., 2014). SIVΔVpx and RT-SHIVΔVpx were more sensitive
to AZT as compared to SIV and RT-SHIV, however sensitivity was not
altered for 3TC and TDF in MDMs (Fig. 4B and C, and Table 2). For
activated CD4þ T cells, the sensitivity towards NRTIs did not
signiﬁcantly change for HIV-1, SIV and RT-SHIV (Fig. 1 and Table 1).
However, deletion of Vpx inﬂuenced the viral sensitivity to AZT, 3TC,
and TDF in activated CD4þ T cells (Fig. 2A C), but not for RAL and
ETR, which do not require phosphorylation for their antiviral
activities.
Treatment of activated CD4þ T cells and MDMs with NRTIs led
to different cellular concentrations of NRTI-TP (Gavegnano et al.,
2013). Huber et al. (2014) hypothesized that kinases associated
with AZT and d4T phosphorylation may be the rate-limiting step
in their activation, and inﬂuence the levels of dNTPs and NRTI-TPs.
Since SAMHD1 hydrolyzes canonical dNTP, but not NRTI-TPs, the
Vpx effect on NRTI sensitivity reduction could be primarily due to
1) increase of dNTP biosynthesis, 2) decrease of dNTP degradation,
and 3) decrease of NRTI-TP synthesis. While it is not clear that
SAMHD1 is directly involved in all of these three possibilities, it is
plausible that Vpx can inﬂuence the NRTI sensitivity using all three
possibilities in different cell types.
Importantly, this work suggests that instead of structural and
enzymatic differences between RTs, Vpx inﬂuences NRTI sensitiv-
ity in different cell types. Therefore, special consideration may be
needed when evaluating the sensitivity proﬁles of NRTIs when
using RT-SHIVs coding for Vpx, since an underestimate of the
antiviral efﬁcacy of NRTIs may be occurring.
Materials and methods
Cells and cell culture
Monocytes were isolated from whole blood (New York Blood
Service, Long Island New York) by using MACSs CD14þ beads as
described previously (Hollenbaugh et al., 2013) and cultured in the
presence of 5 ng/ml human GM-CSF (Miltenyi Biotec). The result-
ing MDMs were utilized on day 7 for all experiments. From
monocyte-depleted PBMCs, MACS CD4 beads were used to enrich
for CD4þ T cells as previously described (Hollenbaugh et al., 2011).
Cells were cryopreserved (10 million cells/ml, 80 1C) until
reanimated for experimentation. Upon reanimation in DMEM (5%
FBS/30 million cells), 60–120 million CD4þ T cells were activated
using 5 mg/ml of PHA (Sigma) and 10 ng/ml IL-2 (NIH AIDS Reagent
Program). On day 3 post-reanimation, fresh medium and 10 ng/ml
IL-2 were added to cells and cells were permitted to expand for a
further 48 h after which cells were utilized in experiments.
Drugs
The following reagents were obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH: Zidovudine (AZT),
Etravirine (ETR) TMC125 (Cat#11609) from Tibotec, Inc., Raltegra-
vir (RAL) (Cat#11680) from Merck & Company, Inc., and tenofovir
disoproxil fumarate (TDF; Cat#10198). 3TC and ddC were pur-
chased from Sigma-Aldrich.
Molecular clones and cloning
DHIV3-GFP plasmid encodes the HIV-1 NL4-3 genome with the
enhanced GFP gene in place of the HIV-1 nef gene and has a
deleted envelope gene (Andersen et al., 2006). pSIVmac239-GFP was
a kind gift from Dr. Diaz-Griffero (Albert Einstein College of
Medicine, NYC). 50-pSHIV, which contained the HIV-1 HXB2 RT
gene, was a kind gift from Dr. North (Emory University). We sub-
cloned the HIV-1 RT from p50–SHIV into pSIVmac239-GFP by
digesting with NheI and PacI followed by site-directed mutagen-
esis (Quikchange, Agilent) of the primer-binding site to make it
complementary to tRNALys sequence (Das et al., 1997). The result-
ing construct is the pSIVmac239-GFP with the HXB2 RT gene instead
of the SIV RT gene. We called the construct ‘pRT-SHIVmac239-GFP0.
Next, pSIVmac239-GFP vector, pRT-SHIVmac239-GFP and pSIVmac239
SpX ΔVpx, (the latter construct kindly provided by NIH AIDS
Reagent Program), were digested with NheI and ClaI. The ΔVpx
fragment was then subcloned into pSIVmac239-GFP and pRT-
SHIVmac239-GFP to generate ‘pSIVmac239-ΔVpx-GFP’ and ‘pRT-
SHIVmac239-ΔVpx GFP’, respectively.
Generation of viruses
293FT cells (Invitrogen) were transfected with 20 mg of pVSV-G
and 40 mg of pDHIV3 (HIV-1), pSIVmac239-GFP (SIV), pRT-SHIVmac239-
GFP (RT-SHIV), pSIVmac239-ΔVpx-GFP (SIVΔVpx), or pRT-SHIVmac239-
ΔVpx-GFP (RT-SHIVΔVpx) via polyethylenimine (PEI; 1 mg/mL) in a
ratio of 1 mg of DNA to 3 ml PEI. Twenty-four hours post-transfection,
the culture medium was removed and replaced with fresh DMEM
containing 5% FBS with penicillin and streptomycin. Cell supernatants
were harvested 48 h and 72 h post-transfection, centrifuged at
2500 rpm for 10 min to remove cellular debris. Virus was concen-
trated from cell supernatants via ultracentrifugation (22,000 rpm for
1.5 h in a SW32Ti rotor) and resuspended in cell culture medium
after a short high-speed centrifugation to remove any excess debris
(13,000 rpm for 1 min) and stored at 80 1C until use. VSV-G-
pseudotyped viruses were assessed ﬁve days post-transduction in
MDMs and 2 days post-transduction in CD4þ T cells for infectivity/
GFP expression using a MACSQuant Analyzer. Data ﬁles were
analyzed using the FlowJo software (TreeStar). Data was graphed
using Prism software.
Evaluation of drug efﬁcacy
Activated CD4þ T cells were seeded into a 96-well plate at
100,000 cells/well. Drugs were diluted from stock concentrations
to 1000 nM and 125 nM for NRTIs and non-NRTIs, respectively.
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Drugs were then serially diluted to achieve 7 total dilutions (in
order to obtain a dose–response curve) and then added to cells
immediately. Cells were permitted to incubate with drugs for 2 h
before the addition of virus and drug was present throughout the
experiment. Seventy-two hours post-infection, cells were treated
with DAPI (0.001 mg/ml), to account for dead cells during FACS
collection (MACSQuant FACS instrument). Data ﬁles were analyzed
using the FlowJo software.
Drug concentrations were prepared for experiments utilizing
MDMs (250,000 cells/well, 24-well plate) as described for CD4þ T
cells above. As with CD4þ T cells, MDMs were also permitted to
incubate with drugs for 2 h prior to infections. Culture medium
was changed 48 h post-infections with fresh medium containing
drug (at concentrations used at experiment initiation). At day 5,
MDMs were harvested by removing medium and adding 250 ml of
2.5% Trypsin to each experimental well and incubated for 5 min at
37 1C, after which time the cells were gently scraped and trans-
ferred to the eppendorf tube and pelleted for 60 s at 6000 rpm.
Pellets were suspended in 50 ml medium contain DAPI (0.001 mg/
ml), to exclude for dead cells, and evaluated for GFP expression via
ﬂow cytometry (MACSQuant FACS machine).
Determination of IC50 values, graphing of dose–response curves and
statistical analysis
Prism software was used for plotting the data. All the data sets
were compared for signiﬁcant differences(*) using Two-way ANOVA
analysis and then Tukey multiple comparison test. To determine IC50
values, the mean values for each independent donor were combined
and evaluated using log[inhibitor] vs. normalized response – variable
slope. Graphs are plotted as the means and standard error of the
means (SEM) for the donors.
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